Latest news with #MereoBioPharma
Yahoo
15 hours ago
- Business
- Yahoo
Exploring High Growth Tech Opportunities in US Markets
Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.36% 60.93% ★★★★★★ Blueprint Medicines 21.12% 60.77% ★★★★★★ Alnylam Pharmaceuticals 23.63% 60.71% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Palo Alto Networks, Inc. is a global provider of cybersecurity solutions with a market capitalization of $130.87 billion. Operations: The company generates revenue primarily from its Security Software & Services segment, amounting to $8.87 billion. Palo Alto Networks' strategic maneuvers, such as its recent partnership with Binary Defense, underscore its commitment to enhancing security operations through AI-driven platforms like Cortex XSIAM. This collaboration not only broadens the implementation and MDR services but also customizes support to fit diverse organizational needs, reflecting Palo Alto's adaptability in a high-stakes cybersecurity landscape. Moreover, their consistent R&D investment, which recently accounted for approximately 12.6% of their revenue, fuels innovations that keep them at the forefront of cybersecurity solutions. These efforts are pivotal as they navigate a competitive market where maintaining technological leadership is crucial for growth and client trust. Take a closer look at Palo Alto Networks' potential here in our health report. Assess Palo Alto Networks' past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★★☆ Overview: Take-Two Interactive Software, Inc. is a global developer, publisher, and marketer of interactive entertainment solutions with a market cap of approximately $42.11 billion. Operations: The company generates revenue primarily through its publishing segment, which accounts for $5.63 billion. Take-Two Interactive Software has been actively expanding its financial and operational scope, as evidenced by recent strategic moves including a $1B public offering aimed at funding acquisitions and debt repayment. This aligns with their aggressive R&D investment strategy, crucial for fostering innovation in the highly competitive gaming sector. Despite reporting a net loss, Take-Two projects significant revenue growth ranging from $5.95B to $6.05B next fiscal year, underpinned by robust annualized revenue and earnings growth rates of 14.2% and 89.3%, respectively. These figures suggest a resilient adaptation to market demands and potential future profitability, positioning them well within the high-growth tech landscape despite current financial setbacks. Click here and access our complete health analysis report to understand the dynamics of Take-Two Interactive Software. Gain insights into Take-Two Interactive Software's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Spotify Technology S.A., along with its subsidiaries, offers audio streaming subscription services globally and has a market capitalization of approximately $145.76 billion. Operations: Spotify generates revenue primarily through its Premium subscription service, which accounts for €14.34 billion, and its Ad-Supported segment, contributing €1.88 billion. Spotify Technology has demonstrated robust financial performance, with a notable increase in sales from EUR 3.64 billion to EUR 4.19 billion year-over-year and an uplift in net income to EUR 225 million. This growth is underpinned by a strategic emphasis on R&D, crucial for sustaining innovation and competitiveness in the dynamic tech landscape; indeed, Spotify's R&D expenses have consistently aligned with its revenue growth, ensuring continuous product evolution and market relevance. Moreover, the company's forward-looking revenue projection of $4.3 billion underscores its operational optimism and potential for sustained expansion within the tech sector. Click here to discover the nuances of Spotify Technology with our detailed analytical health report. Learn about Spotify Technology's historical performance. Explore the 233 names from our US High Growth Tech and AI Stocks screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PANW TTWO and SPOT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has been flat, yet it is up 9.9% over the past year with earnings projected to grow by 15% annually. In this context of steady growth and positive earnings forecasts, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health amidst these conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 21.03% 60.42% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.36% 60.93% ★★★★★★ Blueprint Medicines 21.12% 60.77% ★★★★★★ Alnylam Pharmaceuticals 23.63% 60.71% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 229 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Tenable Holdings, Inc. offers cyber exposure management solutions across various global regions and has a market capitalization of approximately $4.01 billion. Operations: Tenable Holdings generates revenue primarily from its Security Software & Services segment, amounting to $923.20 million. The company operates across the Americas, Europe, the Middle East, Africa, the Asia Pacific, and Japan. Tenable Holdings, despite its current unprofitability, is strategically positioning itself for future profitability with significant leadership and product expansions. The company's recent appointment of experienced executives and the anticipated launch of an expanded Tenable One platform underscore a focused strategy on enhancing cybersecurity capabilities. Notably, Tenable's R&D expenditure has been robust, supporting its aggressive innovation trajectory. This commitment is reflected in its projected earnings growth of 61.1% annually and an ambitious revenue forecast aiming for $970 million to $980 million by year-end. Moreover, the repurchase of 1.6 million shares early this year highlights confidence in their strategic direction amidst a challenging competitive landscape. Click here to discover the nuances of Tenable Holdings with our detailed analytical health report. Gain insights into Tenable Holdings' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Corning Incorporated operates in the optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and globally, with a market cap of approximately $43.23 billion. Operations: The company generates revenue primarily from optical communications ($5.08 billion) and display technologies ($3.91 billion), with additional contributions from specialty materials, life sciences, and Hemlock and emerging growth businesses. Corning's strategic collaborations and technological advancements underscore its potential in high-growth sectors like AI and mobile technologies. Recently, Corning partnered with Broadcom to enhance data center capacities with its optical components for a pioneering ethernet switch, reflecting significant strides in AI infrastructure efficiency. Additionally, the introduction of Gorilla Glass Ceramic 21 in Samsung's latest smartphone exemplifies Corning's influence on mobile durability innovations. These efforts are supported by robust R&D investments totaling $404 million last year, aimed at refining technologies that meet evolving digital demands. With a projected annual earnings growth of 27.9% and revenue increases expected at 9.6% per year, Corning is positioning itself as a key player in essential tech domains despite some financial setbacks like a notable one-off loss impacting recent results. Take a closer look at Corning's potential here in our health report. Evaluate Corning's historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: MNTN, Inc. is a performance TV software company that offers advertising services in the United States with a market capitalization of approximately $1.53 billion. Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $246.27 million. MNTN, recently public following a $187.2 million IPO, illustrates a dynamic shift in tech with its aggressive growth metrics and strategic legal structuring to bolster market presence. Despite current unprofitability, the company is on a trajectory with forecasted earnings growth at an impressive 74.5% annually, significantly outpacing the industry average. This performance is underpinned by substantial R&D investments aimed at pioneering innovations in software and AI technologies, ensuring MNTN remains competitive in a rapidly evolving sector. These efforts are complemented by recent regulatory updates and significant capital raised through equity offerings totaling nearly $700 million, positioning MNTN to capitalize on expanding market opportunities and enhance shareholder value. Click to explore a detailed breakdown of our findings in MNTN's health report. Review our historical performance report to gain insights into MNTN's's past performance. Explore the 229 names from our US High Growth Tech and AI Stocks screener here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TENB GLW and MNTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
22-05-2025
- Health
- Yahoo
Reproductive health startup raises $65M for infertility drugs
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women. The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs. The first, called leflutrozole, is designed to treat infertility in men with low testosterone, while the second, nolasiban, will be studied in women with a gynecological disorder called adenomyosis and as an adjunctive therapy alongside assisted reproductive technologies. 'We are here to fill the critical gaps for patients in reproductive medicine and women's health,' Jean Maire Duvall, CEO and co-founder of ReproNovo, told BioPharma Dive. Founded in 2021, ReproNovo gained rights to the candidates through licensing deals with Mereo BioPharma and ObsEva, respectively. Leflutrozole is a small molecule that works by blocking an enzyme called aromatase. This effect, ReproNovo says, could help stabilize levels of testosterone and address male infertility. Some research has raised concerns about declines in male reproductive health, as fertility rates among women in the U.S. have also fallen. Although infertility impacts both men and women, the pressure and responsibility for solving the issue often falls on the woman. 'We'd like to offer an alternative where the male could be treated directly,' said Duvall. Nolasiban blocks oxytocin receptors, which ReproNovo sees as potentially helpful in managing adenomyosis, a condition where endometrial tissue grows in the uterine walls. Adenomyosis can cause similar symptoms as endometriosis, such as pelvic pain and heavy menstrual bleeding. The condition often occurs in women between the ages of 35 to 50. There are no drugs specifically approved to treat it. ReproNovo is also studying whether nolasiban can improve embryo implantation by reducing uterine contractility and enhancing blood flow amid embryo transfer during in vitro fertilization. While other treatments are available and in development to increase the chances of IVF success, none are approved to support embryo implantation specifically, the company said. The Series A funding round was led by Jeito Capital and co-led by AXA IM Alts and ReproNovo's founding investor M Ventures, the venture arm of Merck KGaA. Ysios Capital and Alsa Ventures also participated. Recommended Reading Women's health faces growing headwinds, despite jump in venture investment
Associated Press
13-05-2025
- Business
- Associated Press
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ('Mereo' or the 'Company'), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. 'As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-out either at the second interim analysis in mid-2025 or at the final analysis in the fourth quarter. We are continuing to invest in the pre-commercial activities for setrusumab to enable a successful launch in our European territory, following potential regulatory approvals,' said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. 'Further, alvelestat is now Phase 3 ready and we are finalizing the trial start-up activities to support our ongoing partnering process. Along with our late-stage pipeline, we believe that continued close management of our cash balance will enable us to support our operations into 2027.' First Quarter 2025 Highlights, Recent Developments, and Anticipated Milestones Setrusumab (UX143) Alvelestat (MPH-966) First Quarter 2025 Financial Results Total research and development ('R&D') expenses decreased by $0.1 million from $4.0 million in the first quarter of 2024 to $3.9 million in the first quarter of 2025. The decrease was primarily due to decreases of $1.2 million and $0.1 million in R&D expenses for alvelestat and etigilimab, offset by an increase of $1.3 million in R&D expenses for setrusumab. The decrease in program expenses for alvelestat was primarily due to undertaking reduced drug formulation and manufacturing activities in preparation for the Phase 3 study in the first quarter of 2025, compared to the first quarter of 2024. The increase in program expenses for setrusumab was primarily driven by amounts due under the manufacturing and supply agreement with our partner, Ultragenyx, ongoing activities related to real-world evidence programs and medical affairs activities in Europe and input into development, regulatory and manufacturing plans with Ultragenyx, who fund the global development of the program pursuant to our license and collaboration agreement. General and administrative expenses increased by $1.4 million from $5.9 million in the first quarter of 2024 to $7.3 million in the first quarter of 2025. The increase was primarily due to the recognition of a $1.7 million reduction in expenses in the first quarter of 2024 for amounts received from our depository to reimburse certain expenses incurred by us in respect of our ADR program, partially offset by a net decrease in employee-related expenses and professional fees. A reimbursement in respect of our ADR program is anticipated in 2025. Net loss for the first quarter of 2025 was $12.9 million, compared to $9.0 million during the first quarter of 2024, primarily reflecting an operating loss of $11.2 million and foreign currency translation loss. As of March 31, 2025, the Company had cash and cash equivalents of $62.5 million, compared to $69.8 million as of December 31, 2024. The Company's guidance remains unchanged, and it continues to expect, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into 2027. This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company's non-core programs. Total ordinary shares issued as of March 31, 2025 were 795,001,444. Total ADS equivalents as of March 31, 2025 were 159,000,288, with each ADS representing five ordinary shares of the Company. About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The Company's partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 study in pediatrics and young adults (5 to 25 years old) for setrusumab in OI and in the Phase 3 study in pediatric patients (2 to <7 years old). The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for osteogenesis imperfecta from the European Commission ('EC') and the FDA, PRIME designation from the EMA, and has Breakthrough Therapy designation and rare pediatric disease designation from the FDA. Alvelestat has received Orphan Designation for AATD from the EC and the FDA, and Fast Track designation from the FDA for AATD-LD. Following results from ASTRAEUS and ATALANTa in AATD-lung disease, the Company has aligned with the FDA and the EMA on the primary endpoints for a Phase 3 pivotal study which, if successful, could enable full approval in both the U.S. and Europe. In addition to the rare disease programs, Mereo has two oncology product candidates, etigilimab, an anti-TIGIT; and navicixizumab for the potential treatment of late-line ovarian cancer. Navicixizumab has been partnered with Feng Biosciences, Inc. in a global licensing agreement that includes milestone payments and royalties. Mereo has also entered into an exclusive global license agreement with ReproNovo SA, a reproductive medicine company, for the development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor. Forward-Looking Statements This press release contains 'forward-looking statements' that involve substantial risks and uncertainties. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words 'believe,' 'expect,' 'anticipate,' 'plan,' 'intend,' 'foresee,' 'should,' 'would,' 'could,' 'may,' 'estimate,' 'outlook' and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. All of the Company's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the Company's dependence on enrollment of patients in its clinical trials; and the Company's dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the 'Risk Factors' section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. Mereo BioPharma Contacts:
